Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1927 1
1948 1
1960 1
1961 3
1963 1
1965 2
1966 1
1968 1
1969 1
1970 3
1974 2
1975 1
1976 2
1977 2
1978 9
1979 2
1980 5
1981 8
1982 5
1983 12
1984 6
1985 5
1986 7
1987 8
1988 8
1989 7
1990 8
1991 8
1992 11
1993 10
1994 22
1995 17
1996 18
1997 20
1998 13
1999 12
2000 14
2001 7
2002 19
2003 10
2004 6
2005 11
2006 6
2007 13
2008 6
2009 9
2010 5
2011 6
2012 11
2013 15
2014 8
2015 4
2016 4
2017 19
2018 18
2019 6
2020 8
2021 10
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

442 results
Results by year
Filters applied: . Clear all
Page 1
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
Fisher MJ, Shih CS, Rhodes SD, Armstrong AE, Wolters PL, Dombi E, Zhang C, Angus SP, Johnson GL, Packer RJ, Allen JC, Ullrich NJ, Goldman S, Gutmann DH, Plotkin SR, Rosser T, Robertson KA, Widemann BC, Smith AE, Bessler WK, He Y, Park SJ, Mund JA, Jiang L, Bijangi-Vishehsaraei K, Robinson CT, Cutter GR, Korf BR; Neurofibromatosis Clinical Trials Consortium, Blakeley JO, Clapp DW. Fisher MJ, et al. Among authors: johnson gl. Nat Med. 2021 Jan;27(1):165-173. doi: 10.1038/s41591-020-01193-6. Epub 2021 Jan 13. Nat Med. 2021. PMID: 33442015 Free PMC article. Clinical Trial.
FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease.
Garcia-Recio S, Thennavan A, East MP, Parker JS, Cejalvo JM, Garay JP, Hollern DP, He X, Mott KR, Galván P, Fan C, Selitsky SR, Coffey AR, Marron D, Brasó-Maristany F, Burgués O, Albanell J, Rojo F, Lluch A, de Dueñas EM, Rosen JM, Johnson GL, Carey LA, Prat A, Perou CM. Garcia-Recio S, et al. Among authors: johnson gl. J Clin Invest. 2020 Sep 1;130(9):4871-4887. doi: 10.1172/JCI130323. J Clin Invest. 2020. PMID: 32573490 Free PMC article.
Defining MAPK interactomes.
Johnson GL. Johnson GL. ACS Chem Biol. 2011 Jan 21;6(1):18-20. doi: 10.1021/cb100384z. ACS Chem Biol. 2011. PMID: 21128644 Review.
Measuring Kinase Activity-A Global Challenge.
Cann ML, McDonald IM, East MP, Johnson GL, Graves LM. Cann ML, et al. Among authors: johnson gl. J Cell Biochem. 2017 Nov;118(11):3595-3606. doi: 10.1002/jcb.26103. Epub 2017 May 31. J Cell Biochem. 2017. PMID: 28464261 Review.
Targeting the Breast Cancer Kinome.
Miller SM, Goulet DR, Johnson GL. Miller SM, et al. Among authors: johnson gl. J Cell Physiol. 2017 Jan;232(1):53-60. doi: 10.1002/jcp.25427. Epub 2016 May 31. J Cell Physiol. 2017. PMID: 27186656 Review.
The dynamic nature of the kinome.
Graves LM, Duncan JS, Whittle MC, Johnson GL. Graves LM, et al. Among authors: johnson gl. Biochem J. 2013 Feb 15;450(1):1-8. doi: 10.1042/BJ20121456. Biochem J. 2013. PMID: 23343193 Free PMC article. Review.
New strategies for targeting kinase networks in cancer.
Yesilkanal AE, Johnson GL, Ramos AF, Rosner MR. Yesilkanal AE, et al. Among authors: johnson gl. J Biol Chem. 2021 Oct;297(4):101128. doi: 10.1016/j.jbc.2021.101128. Epub 2021 Aug 27. J Biol Chem. 2021. PMID: 34461089 Free PMC article. Review.
Pharmacologic targeting of drug-induced enhancers.
Zawistowski JS, Bevill SM, Johnson GL. Zawistowski JS, et al. Among authors: johnson gl. Oncoscience. 2017 Jun 22;4(5-6):43-44. doi: 10.18632/oncoscience.354. eCollection 2017 May. Oncoscience. 2017. PMID: 28781985 Free PMC article. No abstract available.
442 results